Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | Phase I/Ib trial of neoadjuvant relugolix and darolutamide in prostate cancer

Guru Sonpavde • 14 Feb 2025

GU Cancers 2025

Guru Sonpavde, MD, AdventHealth Cancer Institute, Orlando, FL, gives an overview of a Phase I/Ib trial (NCT06631521) evaluating neoadjuvant relugolix and darolutamide before radical prostatectomy in high-risk localized prostate cancer. This all-oral regimen aims to enhance operability, allow rapid testosterone recovery, and serve as a foundation for future combination strategies. Secondary objectives include clinical and pathological response, undetectable PSA nadir rates, and post-operative recovery. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.